View Financial HealthPsykey 배당 및 자사주 매입배당 기준 점검 0/6Psykey 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 01CeCors, Inc. Appoints Michael Maher as Interim CEOCeCors, Inc. announced the appointment of Michael Maher as Interim Chief Executive Officer, effective immediately. Maher brings extensive leadership experience and a proven track record in driving operational efficiencies, compliance excellence and fiscal responsibility, positioning CeCors for sustainable growth. Maher has concurrently been appointed CEO and director of VETCOMM, CeCors' rapidly growing wholly-owned subsidiary focused on veteran claims benefits. His immediate priorities include streamlining operations, bolstering regulatory compliance, and implementing fiscal discipline to maximize value for the Company's client base and shareholders. Michael Maher is a former Navy Nuclear Submariner, U.S. Department of Justice Special Agent of the Federal Bureau of Investigation and has held numerous executive leadership roles globally. He is an alumnus of the FBI cademy, Navy Nuclear Power School, Oxford University, and a senior executive fellow with Harvard's John F. Kennedy School of Government. Under Maher's interim leadership, CeCors will continue to focus on its core mission while exploring new business opportunities and innovative solutions to meet the evolving needs of those they serve. Mr. Maher will oversee the implementation of VETCOMM's 2025 operating agenda, building on operational protocols as the company continues to grow, ensuring best practices across all operating segments.공시 • May 26CECORS, INC. Appoints Kate Monroe as Chief Executive OfficerCECORS, INC. announced the appointment of Marine Corps veteran Kate Monroe as its new Chief Executive Officer (CEO). With her extensive executive experience and strategic acumen, Monroe is poised to successfully lead CeCors in its strategic direction for greater market expansion and increased shareholder value. Kate Monroe is a highly accomplished professional with a distinguished journey. Born in Northern California, she embarked on a path of continuous growth and challenges from an early age. After attending Corban University, Kate recognized her need for a greater challenge, leading her to make the courageous decision to join the Marine Corps. She credits the Marine Corps for shaping her into the person she is, setting her on a trajectory for a successful life and career. Her military background serves as a catalyst, earning her respect and impacting the minds of those she interacts with. Kate's entrepreneurial spirit was instilled in her by her father, which propelled her to numerous successful ventures in various industries. Kate's most recent venture is the founding of VetComm, a veteran's education and benefits company focused on assisting United States veterans who qualify for underutilized annual benefits and owed compensation, resulting in billions of dollars of unclaimed benefits in the United States annually. Kate continues to shape the landscape of veteran support while also bringing her expertise and passion for driving the success of CeCors Inc. Kate Monroe is a tenacious and driven individual who thrives on empowering others to achieve success; her personal triumphs serve as a testament to her ability to inspire and lead. Monroe's appointment as CEO entails heightened responsibility in delivering value to shareholders while navigating the unique dynamics of the public markets. Her role encompasses key responsibilities, including strategic leadership, investor relations, and market expansion. As CEO, Monroe will provide strategic vision and leadership to CeCors, aligning the company's goals with the interests of its subsidiaries and shareholders. She will work closely with the board of directors and executive teams to define and execute the company's strategic direction. Recognizing the importance of maintaining strong relationships with shareholders and the investment community, Monroe will actively engage in investor relations activities. She will communicate the company's performance, growth strategies, and milestones to build trust and confidence among investors. Leading CeCors, Monroe will spearhead efforts to expand the company's market presence through its wholly-owned subsidiaries and continue to enhance shareholder value. She will explore opportunities for strategic partnerships, acquisitions, and organic growth to maximize market opportunities for the company.공시 • Dec 21Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp.Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp on December 19, 2022.공시 • Dec 07PsyKey Inc. Adds Dr. Shahiem Hartley to its Medical Advisory BoardPsyKey Inc. announced the addition of published medical and corporate wellness professional Dr. Shahiem Hartley to its Medical Advisory Board. Dr. Hartley completed a medical, masters, and pharmacy degree in South Africa before moving to Edmonton, Alberta, where he currently practices family medicine. During the pandemic, Dr. Hartley pivoted his business to assist patients with coping strategies, stress, and mental health management. Dr. Hartley then parlayed those strategies to develop a corporate mental wellness consulting company. Dr. Hartley offers individual and large-scale corporate enhancement and mental wellness seminars and training sessions.공시 • Nov 17Psykey, Inc. Appoints Michael J. Mccarthy as Member of Scientific & Medical Advisory BoardCECORS, INC. through its wholly owned subsidiary PsyKey Inc., announce the appointment of Dr. Michael J. McCarthy, Ph.D. to its scientific and medical advisory board. Dr. McCarthy joins PsyKey with over 35 years of experience serving as a consultant to the biopharmaceutical industry and formulating high-impact pharmaceuticals and nutraceuticals. A biochemist and widely published author, Dr. McCarthy offers PsyKey his extensive expertise in securing biomedical patents and intellectual properties. Prior to joining PsyKey, Dr. McCarthy spent eight years at Scripps Research, ranked the most influential institution in the world for its impact on innovation as their biotechnology patent agent, while working on numerous ground-breaking technologies which have had major market influence. Among his many contributions to the biomedical field, Dr. McCarthy developed the "Agent/Enhancer" technology to increase the potency of biochemical factors used in therapeutics for anxiety, cancer, and sleep enhancement. With degrees in Biology and Physics from Benedictine College, Dr. McCarthy attended The Johns Hopkins University School of Medicine, where he participated in the Biochemistry, Cellular and Molecular Biology program. McCarthy went on to earn his Ph.D. from the Department of Biochemistry at Vanderbilt University. His Postdoctoral Studies in Endocrinology at Vanderbilt included developing viral and transgenic systems leading to the reversal of atherosclerosis in laboratory animals.공시 • Nov 01CECORS, INC. Announces Appointment of John Gustin as Head of Global Business DevelopmentCECORS, INC. announced the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest-growing nutritional companies and brands in direct sales. Moreover, Gustin has led the effort to develop and patent numerous successful formulations for functional health and wellness products, and has authored numerous published articles related to immunology, diabetes, obesity and sports nutrition. One such patent, “# 5,914,326 Method for Promoting Weight and Fat Loss” was licensed to the former US Surgeon General Dr. C. Everett Koop. As a consultant, Gustin played a prominent role in the growth of numerous direct market giants, such as Nikken, Isotonix and NuSkin, providing guidance in product development and marketing strategies. He is generally credited with introducing the fat-burning, staple supplement Garcinia Cambogia to the U.S. market and helped to conduct the first human clinical studies. As a corporate member of United Sciences of America, Inc., Gustin helped the direct market company become the second fastest growing corporation in history with over $100 million in sales in its first nine months of operation. Gustin was also a founder and key executive of Evolv Health, LLC, makers of science-based functional beverages, which realized annual revenues exceeding $80 million. His discoveries and the brands he has helped develop have been viewed by millions on CNN, NBC, CBS, ABC and Fox news.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 CEOS 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: CEOS 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Psykey 배당 수익률 vs 시장CEOS의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CEOS)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Healthcare Services)1.3%분석가 예측 (CEOS) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CEOS 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CEOS 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CEOS 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: CEOS 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 21:43종가2026/05/22 00:00수익2008/09/30연간 수익2007/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Psykey, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 01CeCors, Inc. Appoints Michael Maher as Interim CEOCeCors, Inc. announced the appointment of Michael Maher as Interim Chief Executive Officer, effective immediately. Maher brings extensive leadership experience and a proven track record in driving operational efficiencies, compliance excellence and fiscal responsibility, positioning CeCors for sustainable growth. Maher has concurrently been appointed CEO and director of VETCOMM, CeCors' rapidly growing wholly-owned subsidiary focused on veteran claims benefits. His immediate priorities include streamlining operations, bolstering regulatory compliance, and implementing fiscal discipline to maximize value for the Company's client base and shareholders. Michael Maher is a former Navy Nuclear Submariner, U.S. Department of Justice Special Agent of the Federal Bureau of Investigation and has held numerous executive leadership roles globally. He is an alumnus of the FBI cademy, Navy Nuclear Power School, Oxford University, and a senior executive fellow with Harvard's John F. Kennedy School of Government. Under Maher's interim leadership, CeCors will continue to focus on its core mission while exploring new business opportunities and innovative solutions to meet the evolving needs of those they serve. Mr. Maher will oversee the implementation of VETCOMM's 2025 operating agenda, building on operational protocols as the company continues to grow, ensuring best practices across all operating segments.
공시 • May 26CECORS, INC. Appoints Kate Monroe as Chief Executive OfficerCECORS, INC. announced the appointment of Marine Corps veteran Kate Monroe as its new Chief Executive Officer (CEO). With her extensive executive experience and strategic acumen, Monroe is poised to successfully lead CeCors in its strategic direction for greater market expansion and increased shareholder value. Kate Monroe is a highly accomplished professional with a distinguished journey. Born in Northern California, she embarked on a path of continuous growth and challenges from an early age. After attending Corban University, Kate recognized her need for a greater challenge, leading her to make the courageous decision to join the Marine Corps. She credits the Marine Corps for shaping her into the person she is, setting her on a trajectory for a successful life and career. Her military background serves as a catalyst, earning her respect and impacting the minds of those she interacts with. Kate's entrepreneurial spirit was instilled in her by her father, which propelled her to numerous successful ventures in various industries. Kate's most recent venture is the founding of VetComm, a veteran's education and benefits company focused on assisting United States veterans who qualify for underutilized annual benefits and owed compensation, resulting in billions of dollars of unclaimed benefits in the United States annually. Kate continues to shape the landscape of veteran support while also bringing her expertise and passion for driving the success of CeCors Inc. Kate Monroe is a tenacious and driven individual who thrives on empowering others to achieve success; her personal triumphs serve as a testament to her ability to inspire and lead. Monroe's appointment as CEO entails heightened responsibility in delivering value to shareholders while navigating the unique dynamics of the public markets. Her role encompasses key responsibilities, including strategic leadership, investor relations, and market expansion. As CEO, Monroe will provide strategic vision and leadership to CeCors, aligning the company's goals with the interests of its subsidiaries and shareholders. She will work closely with the board of directors and executive teams to define and execute the company's strategic direction. Recognizing the importance of maintaining strong relationships with shareholders and the investment community, Monroe will actively engage in investor relations activities. She will communicate the company's performance, growth strategies, and milestones to build trust and confidence among investors. Leading CeCors, Monroe will spearhead efforts to expand the company's market presence through its wholly-owned subsidiaries and continue to enhance shareholder value. She will explore opportunities for strategic partnerships, acquisitions, and organic growth to maximize market opportunities for the company.
공시 • Dec 21Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp.Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp on December 19, 2022.
공시 • Dec 07PsyKey Inc. Adds Dr. Shahiem Hartley to its Medical Advisory BoardPsyKey Inc. announced the addition of published medical and corporate wellness professional Dr. Shahiem Hartley to its Medical Advisory Board. Dr. Hartley completed a medical, masters, and pharmacy degree in South Africa before moving to Edmonton, Alberta, where he currently practices family medicine. During the pandemic, Dr. Hartley pivoted his business to assist patients with coping strategies, stress, and mental health management. Dr. Hartley then parlayed those strategies to develop a corporate mental wellness consulting company. Dr. Hartley offers individual and large-scale corporate enhancement and mental wellness seminars and training sessions.
공시 • Nov 17Psykey, Inc. Appoints Michael J. Mccarthy as Member of Scientific & Medical Advisory BoardCECORS, INC. through its wholly owned subsidiary PsyKey Inc., announce the appointment of Dr. Michael J. McCarthy, Ph.D. to its scientific and medical advisory board. Dr. McCarthy joins PsyKey with over 35 years of experience serving as a consultant to the biopharmaceutical industry and formulating high-impact pharmaceuticals and nutraceuticals. A biochemist and widely published author, Dr. McCarthy offers PsyKey his extensive expertise in securing biomedical patents and intellectual properties. Prior to joining PsyKey, Dr. McCarthy spent eight years at Scripps Research, ranked the most influential institution in the world for its impact on innovation as their biotechnology patent agent, while working on numerous ground-breaking technologies which have had major market influence. Among his many contributions to the biomedical field, Dr. McCarthy developed the "Agent/Enhancer" technology to increase the potency of biochemical factors used in therapeutics for anxiety, cancer, and sleep enhancement. With degrees in Biology and Physics from Benedictine College, Dr. McCarthy attended The Johns Hopkins University School of Medicine, where he participated in the Biochemistry, Cellular and Molecular Biology program. McCarthy went on to earn his Ph.D. from the Department of Biochemistry at Vanderbilt University. His Postdoctoral Studies in Endocrinology at Vanderbilt included developing viral and transgenic systems leading to the reversal of atherosclerosis in laboratory animals.
공시 • Nov 01CECORS, INC. Announces Appointment of John Gustin as Head of Global Business DevelopmentCECORS, INC. announced the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest-growing nutritional companies and brands in direct sales. Moreover, Gustin has led the effort to develop and patent numerous successful formulations for functional health and wellness products, and has authored numerous published articles related to immunology, diabetes, obesity and sports nutrition. One such patent, “# 5,914,326 Method for Promoting Weight and Fat Loss” was licensed to the former US Surgeon General Dr. C. Everett Koop. As a consultant, Gustin played a prominent role in the growth of numerous direct market giants, such as Nikken, Isotonix and NuSkin, providing guidance in product development and marketing strategies. He is generally credited with introducing the fat-burning, staple supplement Garcinia Cambogia to the U.S. market and helped to conduct the first human clinical studies. As a corporate member of United Sciences of America, Inc., Gustin helped the direct market company become the second fastest growing corporation in history with over $100 million in sales in its first nine months of operation. Gustin was also a founder and key executive of Evolv Health, LLC, makers of science-based functional beverages, which realized annual revenues exceeding $80 million. His discoveries and the brands he has helped develop have been viewed by millions on CNN, NBC, CBS, ABC and Fox news.